187 related articles for article (PubMed ID: 18271706)
1. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
Lautenschlager M; Heinz A
Expert Rev Neurother; 2008 Feb; 8(2):193-200. PubMed ID: 18271706
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
3. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
5. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
[TBL] [Abstract][Full Text] [Related]
12. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
Canuso CM; Battisti WP
Expert Opin Pharmacother; 2010 Oct; 11(15):2557-67. PubMed ID: 20854185
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Janicak PG; Wu JH; Mao L
Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
[TBL] [Abstract][Full Text] [Related]
17. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone: a new extended-release oral atypical antipsychotic.
Dlugosz H; Nasrallah HA
Expert Opin Pharmacother; 2007 Oct; 8(14):2307-13. PubMed ID: 17927485
[TBL] [Abstract][Full Text] [Related]
19. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]